News & Updates
Filter by Specialty:
Intravesical onabotA instillation safe, but with no clear benefit in urinary incontinence
The intravesical instillation of onabotulinumtoxinA (onabotA) for refractory overactive bladder in urinary incontinence is generally safe and well-tolerated, but demonstrates no significant efficacy advantage over placebo, according to a recent study.
Intravesical onabotA instillation safe, but with no clear benefit in urinary incontinence
28 Jul 2022
Paternal IBD medication use before conception carries no excess risk of childhood infections
Fathers’ exposure to anti-inflammatory or immunosuppressive medications for inflammatory bowel disease (IBD) prior to conception does not appear to contribute to a significantly increased risk of childhood infections, a study has found.
Paternal IBD medication use before conception carries no excess risk of childhood infections
28 Jul 2022
Neutrophils release more cytokines in DM, HFpEF patients
In patients with type 2 diabetes mellitus (DM) or heart failure with preserved ejection fraction (HFpEF), neutrophils seem to secrete more cytokines, contributing to low-grade chronic inflammation, a recent study reports.
Neutrophils release more cytokines in DM, HFpEF patients
27 Jul 2022
Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis
For women with acute uncomplicated cystitis, treatment regimens that include third- and fourth-generation quinolones and pivmecillinam can be administered in shorter courses, which perform similarly to the currently recommended regimens in terms of achieving symptomatic cure, according to the results of a meta-analysis presented at the 37th Annual European Association of Urology (EAU) Congress.
